McGauran Monica, Hyde Simon, Perera Sharnel, Lloyd Mike, Naidoo Mahendra, Sandhu Sherine, Knights Tahlia, Whitely Aleesha, Pritchard Natasha, Zalcberg John, Rome Robert
Department of Gynaecological Oncology, Mercy Hospital for Women, 163 Studley Rd, Heidelberg, VIC 3084, Australia; Department of Obstetrics & Gynaecology, University of Melbourne, 163 Studley Rd, Heidelberg, VIC 3084, Australia.
Department of Gynaecological Oncology, Mercy Hospital for Women, 163 Studley Rd, Heidelberg, VIC 3084, Australia; Department of Obstetrics & Gynaecology, University of Melbourne, 163 Studley Rd, Heidelberg, VIC 3084, Australia.
Gynecol Oncol. 2025 Sep;200:72-79. doi: 10.1016/j.ygyno.2025.07.015. Epub 2025 Jul 22.
The National Gynae-Oncology Registry (NGOR) is an Australian Clinical Quality Registry (CQR). This study reports data on surgical outcomes in patients who underwent cytoreductive surgery for Stage III-IV epithelial Ovarian/Tubal/Peritoneal (OTP) cancer between 2017 and 2022. This study aims to understand rates of perioperative adverse events, complete and optimal cytoreduction, and factors that contribute to this in addition to comparing overall survival (OS) in those who undergo primary cytoreduction (PCS) versus interval cytoreduction (ICS). In doing so, this study aims to evaluate current Australian practice.
All women with Stage III-IV epithelial OTP cancer who underwent cytoreductive surgery between 2017 and 2022 registered with the NGOR were included (N = 1084). Outcomes included: rates of postoperative complications (Clavien Dindo Grade III+), PCS and ICS, complete and optimal cytoreduction, OS, intraoperative complications, and the effects of rurality, performance status, age and socioeconomic status on these outcomes.
PCS was undertaken in 470 (43 %) patients and ICS in 614 (57 %) patients. Postoperative complications were more common in those who underwent PCS versus ICS (p = 0.025 and p = 0.009 respectively). Optimal cytoreduction (macroscopic residual disease <1 cm) was more commonly achieved at ICS (p = 0.047). No difference was observed between groups for complete cytoreduction. Median OS was 4.1 years [IQR 3.9-4.4] with those undergoing PCS surviving longer than those who undergo ICS after propensity matching (p < 0.001).
ICS was associated with less perioperative morbidity, and increased rates of optimal cytoreduction when compared with PCS in patients with Stage III-IV epithelial OTP cancer. PCS was, however, associated with improved overall survival in this registry cohort. This is consistent with international literature and this study uses national CQR data to report on current Australian practice.
国家妇科肿瘤登记处(NGOR)是澳大利亚的一个临床质量登记处。本研究报告了2017年至2022年间接受减瘤手术治疗III-IV期上皮性卵巢/输卵管/腹膜(OTP)癌患者的手术结果数据。本研究旨在了解围手术期不良事件的发生率、完全减瘤和最佳减瘤情况以及促成这些情况的因素,此外还比较接受初次减瘤(PCS)与间隔减瘤(ICS)患者的总生存期(OS)。通过这样做,本研究旨在评估澳大利亚目前的做法。
纳入2017年至2022年间在NGOR登记的所有接受减瘤手术的III-IV期上皮性OTP癌女性患者(N = 1084)。结果包括:术后并发症发生率(Clavien Dindo III+级)、PCS和ICS、完全减瘤和最佳减瘤、OS、术中并发症,以及农村地区、体能状态、年龄和社会经济状况对这些结果的影响。
470例(43%)患者接受了PCS,614例(57%)患者接受了ICS。接受PCS的患者术后并发症比接受ICS的患者更常见(分别为p = 0.025和p = 0.009)。ICS时更常实现最佳减瘤(肉眼残留病灶<1 cm)(p = 0.047)。两组在完全减瘤方面未观察到差异。倾向匹配后,中位OS为4.1年[四分位间距3.9 - 4.4],接受PCS的患者比接受ICS的患者存活时间更长(p < 0.001)。
与III-IV期上皮性OTP癌患者的PCS相比,ICS与围手术期发病率较低以及最佳减瘤率增加相关。然而,在这个登记队列中,PCS与总体生存期改善相关。这与国际文献一致,并且本研究使用国家临床质量登记处数据报告了澳大利亚目前的做法。